We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sarossa | SARS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.52 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.52 | 1.52 |
| Top Posts |
|---|
Posted at 09/6/2020 13:03 by waldron source : Dow Jones NewsDanaher Unit Unveils Sars-CoV-2/Flu A/Flu B/RSV Combo Test Alert By Colin Kellaher Danaher Corp.'s Cepheid unit on Tuesday said it has developed a four-in-one test to detect Sars-CoV-2, Flu A, Flu B and respiratory syncytial virus from a single patient sample. The Sunnyvale, Calif., molecular-diagnostic Cepheid said the test will aid global efforts in the fight against Covid-19 during the upcoming respiratory virus season, as all four infections have similar patient presentations but different treatment and management pathways, making accurate detection and differentiation critical. Cepheid said it will pursue U.S. Food and Drug Administration approval of the test under the agency's emergency use authorization pathway. Write to Colin Kellaher at colin.kellaher@wsj.c (END) Dow Jones Newswires June 09, 2020 07:41 ET (11:41 GMT) |
Posted at 19/11/2015 11:44 by johnsmith321 Hi Hlp_4U,I agree with you a revaluation is needed as SLN has halved in price since the last annual report. They bought £4M of SLN at 200p, then 300K at 240p. PHC is down 20%. GVC is also down. I think more than a £2M loss will be seen in the P+L unfortunately. I guess they may need to do more buybacks this years otherwise the NAV per share will be way down as well. GVC will go back to 450p once the overhang of people who do not like the merger/dividend holiday go. The same thing happened at Optimal payments. Once the merger is completed, it will lead to a improvement in price as will the move to the main market. How low (1.5p) are the BOD going to let Sarossa go before they do something. The original Sarossa cornerstone investors are way down. They need to bring in another cornerstone investor to hover up the overhang in shares otherwise this will continue down. In Adams plc, cornerston investors own 89.6%. I think they should have the same arrangement. |
Posted at 02/10/2015 11:50 by johnsmith321 SARS price ticking up to 1.8p. With only 100M shares. I agree that NAV is down at the moment, but I think PHC and SLN will go back up to 100p and 300p soon.No yield for GVC for the first year as with the last acquisition. The acquisition should stop GVC being dependent on any single source for more 10% earnings. In addition the move up to the main market should be positive for the share price. They also promised to maintain same rate of dividend once acquisition is completed. |
Posted at 21/5/2015 13:41 by johnsmith321 I have just noticed Sarossa just bought all of BVF Partners shares (44,771,610) during the buyback. They are more interested in investing in full biotechs, so no surprise. |
Posted at 08/1/2015 19:48 by johnsmith321 Hi Primachm00,Thanks for the information. I do not follow the OTC market, but I was curious about your comment on the trade. It looks horribly illiquid and the buy-sell spread must be sky high. I guess you like to trade the market because of the large price jumps? During the change of Corporate Structure (SRC to SARS) they said "the Old Sarossa American Depositary Receipt (ADR) program will not be replicated by new sarossa". Maybe they have not yet stopped it! |
Posted at 08/1/2015 09:34 by johnsmith321 Hi Primachm00,Do you have a link for the OTC market announcement in New York? I could not find the sars buy. I thought the listing in America was closed during the recent re-listing process. |
Posted at 14/11/2014 22:22 by primachm00 For those of you who don't follow OTC market in New York, it might be of intrstto note that some nut job bought today 15k sars at $0.075. Compared to todays price in UK equal to gbp 1.89 or approx $0.03. True OTC mkt for sars is thinly traded,but to pay such a premium boggles the mind!!!! |
Posted at 09/11/2014 01:06 by primachm00 Dont see PHC increase reflected in sars pricing |
Posted at 07/11/2014 12:30 by callumross Recent strong rise in PHC means further increase of around £1m in the value of the SARS holding since 30th June. SLN about the same, GVC up 10% and CTH down 10% since then so my calculation of net assets is that they currently stand at around 2.8p per share. |
Posted at 30/9/2014 16:35 by callumross Just noticed this re GVC options: Nice £1m profit for no outlay with GVC shares trading at £5 today!GVC Holdings PLC (AIM:GVC), the multinational sports betting and gaming group, announces the exercise of 343,053 share options (the "Options") by Sarossa Capital Limited (previously known as Antisoma plc). As disclosed in the Company's prospectus dated 25 January 2013, GVC granted, or agreed to grant Antisoma plc options over a total of 343,053 ordinary shares of €0.01 par value each in the capital of the Company ("Ordinary Shares"), pursuant to GVC's acquisition of Sportingbet plc, which completed in March 2013. The Options were granted at market price on the date of their respective grants, but with a dividend credit mechanism which adjusted the Options' exercise prices relative to all dividends declared by GVC from the date of the grants up until exercise. The Options' average exercise price is therefore approximately £1.89 per share. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
